Abstract | Mycobacterium tuberculosis survives in antigen-presenting cells (APCs) such as macrophages and dendritic cells. APCs present antigens in association with major histocompatibility complex (MHC) class II molecules to stimulate CD4 + T cells, and this process is essential to contain M. tuberculosis infection. Immune evasion allows M. tuberculosis to establish persistent or latent infection in macrophages and results in Toll-like receptor 2 (TLR2)-dependent inhibition of MHC class II transactivator expression, MHC class II molecule expression and antigen presentation. This reduction of antigen presentation might reflect a general mechanism of negative-feedback regulation that prevents excessive T cell-mediated inflammation and that M. tuberculosis has subverted to create a niche for survival in infected macrophages and evasion of recognition by CD4 + T cells.
Mycobacterium tuberculosis is an intracellular pathogen that infects phagocytic antigen-presenting cells (APCs) in the lung, including alveolar macrophages, lung macrophages and dendritic cells (DCs). In these cells, M. tuberculosis survives in modified phagosomes and uses multiple mechanisms to evade both innate and adaptive host immunity, including inhibition of phagosome maturation, resistance to innate microbicidal mechanisms and cytokine-mediated host defences, and, as reviewed here, inhibition of antigen presentation.
CD4
+ T cells and the major histocompatibility complex (MHC) class II molecules that induce CD4 + T cell responses are central to host resistance to M. tuberculosis [1] [2] [3] [4] [5] [6] . In mice, between 1 and 3 weeks after infection, M. tuberculosis-specific T cells appear in the lungs, interferon-γ (IFNγ) is expressed (mainly by CD4 + T cells, but also by other cells) and the bacterial burden is controlled. In addition to IFNγ production, CD4 + T cells can kill M. tuberculosis-infected target cells and provide help for other T cell subsets such as CD8 + T cells and γδ T cells, which are important for control of M. tuberculosis infection. Thus, the mechanisms involved in MHC class II antigen processing and presentation, which are required for CD4 + T cell activation, are crucial for controlling M. tuberculosis infection (FIG. 1) .
In humans, 9 out of every 10 healthy individuals control M. tuberculosis in the lungs when infected with the bacterium. The pathogen is not eliminated, however, and a few mycobacteria can persist for years, residing inside macrophages in granulomas and evading elimination by the host immune response. This persistence allows progression to active tuberculosis (TB), either as the progressive primary disease or, years later, as reactivation TB when T cell immunity fails (FIG. 1) .
Multiple mechanisms contribute to the ability of M. tuberculosis to survive in the host. In this Review, we focus on the mechanisms that allow M. tuberculosis to evade CD4 + T cell immunity. Priming of M. tuberculosis-specific T cells is not inhibited by M. tuberculosis, although there is a poorly understood lag period before priming of CD4 + T cells 7, 8 and CD8 + T cells 9 , during which bacterial proliferation continues in the lung. In fact, the M. tuberculosis cell wall is rich in molecules with adjuvant activity (not all of which is mediated by Toll-like receptors (TLRs)) that readily induce immune responses in animal models and in humans. M. tuberculosis infection in humans results in conversion of the tuberculin skin test result from negative to positive, which is indicative of strong CD4 + T cell responses to M. tuberculosis proteins in vivo. This in vivo CD4 + T cell response is associated with substantial IFNγ production and is readily detected ex vivo. After priming, however, CD4 + T cells target the lung but do not eradicate M. tuberculosis. This suggests that effector CD4 + T cells fail to recognize M. tuberculosisinfected cells. One mechanism by which this can occur is through inhibition of antigen presentation by MHC class II molecules. . Although some reports suggest that mycobacteria inhibit Janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling or IFNγ receptor expression 29, 30 , most studies have indicated that these proximal steps in IFNγ signalling are not inhibited by M. tuberculosis 20, [22] [23] [24] . Consistent with the preservation of proximal IFNγ signalling, most IFNγ-induced genes are not inhibited by M. tuberculosis M. tuberculosis lipoproteins and TLR2. TLR2 forms heterodimers with either TLR1 or TLR6 for recognition of triacylated or diacylated lipopeptides, respectively [44] [45] [46] [47] [48] , or the corresponding bacterial lipoproteins. Lipopeptide-induced association of the TLR1 and TLR2 extracellular domains has been characterized by X-ray crystallography, which revealed that the cysteine side chain-linked diacylglycerol moiety of the lipoprotein ligand extends its acyl chains into a hydrophobic pocket in TLR2, and the N-linked acyl chain of the ligand interacts with TLR1 (REF. 44 ).
Bacterial lipoproteins are made as pre-prolipoproteins with an amino-terminal signal sequence 49 (FIG. 2a) . They are processed by a pre-prolipoprotein diacyl glyceryl transferase (Lgt) 50 , which catalyses the thioether linkage of a diacylglycerol moiety to the cysteine immediately following the signal sequence. Then, lipoprotein signal peptidase (LspA) cleaves the signal sequence 51, 52 , and apolipoprotein N-acyltransferase (Lnt) adds an N-linked acyl chain concurrently with transport across the inner membrane 52 . This pathway for synthesis has been demonstrated in a wide range of bacterial species, including Escherichia coli, and mycobacterial homologues of both Lgt and LspA have been identified 51, 53 . Thus, mature mycobacterial lipoproteins have an amino-terminal, triacylated cysteine residue, although the exact biochemical structure of the acyl chains remains poorly defined.
Glycolipids and other mycobacterial agonists of TLR2.
A second class of acylated mycobacterial TLR2 agonists consists of cell wall glycolipids [54] [55] [56] , including lipoarabinomannan (LAM), lipomannan (LM) and phosphatidylinositol mannoside (PIM) 54, [57] [58] [59] [60] (FIG. 2b) . All three contain a PIM core structure with 2-4 acyl chains [60] [61] [62] [63] . These glycolipids, like triacylated lipopeptides, signal through TLR2-TLR1 heterodimers 45, 64 . PIM, LM and LAM vary in their potency as TLR2 agonists, which is possibly influenced by both the carbohydrate structure and the acylation state of the glycolipid 59 ; for example, triacylated LM is a TLR2 agonist, whereas diacylated LM is not proinflammatory 60 . The mannose-capped form of LAM that is expressed by M. tuberculosis (ManLAM) is less potent than the LAM that is expressed by other mycobacteria, such as Mycobacterium smegmatis 55, 65, 66 . Other mycobacterial agonists of TLR2 could include trehalose dimycolate, which has been implicated by some studies in signalling through TLR2, in part 67 .
Consequences of TLR signalling
Although TLR signalling enhances both the innate and adaptive immune responses, it can also downregulate some immune functions. TLR2, in particular, has been implicated in the downregulation or deviation of the immune response through the induction of interleukin-10 (IL-10) and T helper 2 cell or regulatory T cell responses, for example 68 . Prolonged TLR signalling might provide homeostatic feedback regulation that limits the extent of the induced responses. Although TLR signalling in APCs induces microbicidal and inflammatory effectors, de novo MHC class II antigen processing and presentation is inhibited by prolonged signalling with agonists of TLR2 (REFS 32,40,41), TLR9 and TLR4 . Downregulation of antigen presentation is not specific to M. tuberculosis, as it can be induced by components from many microorganisms, but it could be especially pronounced during persistent infection with intravacuolar pathogens that survive microbicidal mechanisms and that can persistently colocalize with TLRs in phagosomes for prolonged TLR signalling (TLR2 can be recruited to phagosomes as well as reside on the plasma membrane 47, 73 
Regulatory T cell
A CD4 + T cell that naturally expresses high levels of CD25 (the IL-2 receptor subunit-α) and the transcription factor forkhead box P3 (FOXP3) and that has suppressive regulatory activity towards effector T cells and other immune cells.
Pyogenic bacterium
A pus-forming bacterium that is associated with exudative inflammation and neutrophil recruitment. TLR signalling by M. tuberculosis generally promotes host immunity, but it can also result in downregulation of antigen presentation in a subset of APCs. As discussed below, the effects of TLR signalling in mycobacterial infection can include both containment of infection during rapid mycobacterial growth and inflammation, and facilitation of the persistence of a small number of bacilli within APCs when adaptive immunity controls M. tuberculosis growth. The ability to take advantage of negative-feedback regulation in macrophages could explain, in part, one of the main paradoxes of the hostpathogen interaction in M. tuberculosis infection: that an organism that elicits strong innate immune responses, through multiple adjuvant-like molecules in its cell wall, as well as strong T cell responses is able to survive and persist in APCs, which are the 'launch pad' of the host's adaptive immune system.
Mechanisms of inhibiting antigen presentation
Transcriptional control of MHC class II might be an important mechanism in the regulation of APC function during infection with M. tuberculosis. The MHC class II transactivator (CIITA) is the master transcriptional regulator of MHC class II molecules [96] [97] [98] [99] [100] [101] [102] . CIITA also regulates transcription of both the invariant chain, which functions as a chaperone to guide MHC class II molecules to antigen-processing compartments, and human leukocyte antigen HLA-DM (histocompatibility protein H2-DM in the mouse), which catalyses the exchange of peptides bound to MHC class II molecules to facilitate binding of antigenic peptides during intracellular antigen processing [102] [103] [104] . CIITA does not bind directly to MHC class II promoters; it coordinates the assembly and action of numerous transcription factors (for example, the regulatory factor X (RFX) family, nuclear transcription factor Y (NFY) and cyclic AMPresponsive-element-binding (CReB) proteins), resulting in the induction of MHC class II transcription.
CIITA expression is controlled through three promoters (pI, pIII and pIV) that drive expression of CIITA types I, III and IV, which incorporate different first exon sequences 97 . Different APC types use different CIITA promoters and control these promoters by various mechanisms 105 . Macrophages use pI and pIV, DCs use pI and B lymphocytes use pIII 106 . In macrophages, pI and pIV are both responsive to IFNγ (that is, IFNγ induces CIITA, which induces expression of MHC class II genes); in immature DCs, pI drives expression of CIITA type I independently of IFNγ 106 . Following their synthesis in the endoplasmic reticulum, MHC class II molecules associate with the invariant chain (FIG. 3) . The invariant chain serves as a surrogate ligand before the loading of MHC class II molecules with antigenic peptides, and its cytoplasmic tail directs targeting of MHC class II molecules from the Golgi complex to late endocytic compartments or phagolysosomes that contain internalized antigen and vacuolar proteases. In these compartments, vacuolar proteases process the antigen to produce antigenic peptides and also catabolize the invariant chain. HLA-DM catalyses the dissociation of a peptide fragment of the invariant chain that occupies the peptide-binding groove of the MHC class II molecule to allow association of antigenic peptides. 35 , indicating that the inhibitory mechanism involves steps that dictate these delayed kinetics. This is consistent with a model that we have proposed (FIG. 4) , in which TLR signalling initiates a series of steps that result in decreased expression of MHC class II and other molecules that contribute to antigen processing and presentation 19,21,23,32,40 . The signalling pathway includes a role for mitogenactivated protein kinase (MAPK) activation 26 , a possible role for nitric oxide 107 and the induction of inhibitory transcription factors (for example, CCAAT/enhancer-binding proteins(C/eBPs)) 25 . It remains unclear whether these effects are mediated by direct TLR2 signalling or by TLR2-induced cytokines, including IL-6 (REFS 108,109); our studies with IL-10-knockout cells indicate that IL-10 is not required for the inhibitory effect (w.H.B., C.V.H. and e. Noss unpublished data). The result is decreased expression of CIITA mRNA (associated with decreased histone acetylation at both the pI and pIV promoters) 20 ,23,25,26,38 , consequent decreased transcription and decay of MHC class II mRNA 23, 35 , decay of nascent MHC class II molecules transiting through the endoplasmic reticulum and Golgi and decay of the pool of nascent MHC class II molecules in antigen processing compartments (which, alone, can take several hours in macrophages). 110 . To study the interference with antigen processing and presentation that is independent of MHC class II molecule expression requires functional assessment of antigen presentation, and this is more difficult than simply measuring the MHC class II molecules on APCs. Mechanisms that inhibit antigen processing and presentation with little effect on MHC class II molecule expression might be more important in certain human macrophage populations in which TLR2 stimulation results in notable inhibition of MHC class II antigen presentation with more subtle effects on MHC class II levels 111 . M. tuberculosis can also inhibit post-translational functions of MHC class II molecules 34 and can blunt antigenprocessing mechanisms (for example, through inhibition of phagosome maturation 112 , although this does not seem to substantially block the processing of M. tuberculosis antigens [112] [113] [114] ). Although post-translational regulation can alter MHC class II function in important ways (for example, by regulating MHC class II molecule stability during DC maturation), most studies suggest that the major cause of decreased antigen presentation by M. tuberculosis-infected macrophages is decreased MHC . Infected DCs migrate to draining mediastinal lymph nodes 116 . DCs are the primary APCs for naive T cells and are essential to 'prime' T cells to become effector and memory cells. Macrophages are excellent activators of effector and memory T cells (for example, at sites of infection), although they are not important for priming T cell responses. As M. tuberculosis can infect both macrophages and DCs, the differences between these cells in MHC class II antigen presentation and its regulation by M. tuberculosis have important implications for the activation of naive and effector CD4 + T cells (FIG. 5) . Macrophages and DCs differ in how MHC expression is regulated in response to TLR signalling. Prolonged TLR signalling (that is, signalling for > 24 hours) reduces MHC class II molecule levels in macrophages 23, 32, 35, 40, 69, 111 . By contrast, TLR agonists drive DCs to undergo maturation, which includes their migration from peripheral sites to lymph nodes and enhances levels of MHC class II molecules and co-stimulators, resulting in increased antigen presentation to naive T cells in lymph nodes [119] [120] [121] [122] . Importantly, the increased levels of MHC class II molecules on mature DCs is due to the increased stability of the proteins 121, 123 , which results from the decreased ubiquitylation of the MHC class II molecules on maturation of DCs, leading to decreased ubiquitin-dependent endocytosis and degradation of the proteins [124] [125] [126] . Although the regulation of MHC class II molecule expression differs in macrophages and DCs, owing to different post-translational mechanisms for the control of MHC class II molecule stability, the effects of TLR signalling on the transcriptional regulation of MHC class II genes are similar and include decreases in the expression of CIITA and the MHC class II genes. Thus, DCs reduce the levels of CIITA and MHC class II mRNAs upon maturation 106, 127 , which is similar to the reduction in CIITA and MHC class II mRNA levels that is seen in macrophages after TLR signalling 19, 21, 23, 32, 35 .
In vitro exposure to M. tuberculosis or its lipoproteins drives DC maturation and the increased expression of co-stimulators and MHC class II molecules 41, [128] [129] [130] [131] , despite decreased CIITA expression and MHC class II molecule synthesis. Antigen processing and the generation of peptide-MHC class II complexes before the loss of MHC class II molecule synthesis allows infected DCs to present mycobacterial antigens to T cells 32, 132 . Despite the proposal that TLR stimulation increases DC antigen presentation, mycobacterial infection might interfere with MHC class II antigen processing and the presentation of M. tuberculosis antigens by DCs. The ManLAM of M. tuberculosis is a DC-SIGN ligand on DCs 133 that can inhibit DC maturation
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. Some in vitro studies indicate that infection of DCs with M. bovis BCG ultimately leads to loss of MHC class II molecules on DCs 134 , as observed in macrophages, making DCs another possible niche for immune evasion by mycobacteria. In addition, induction of DC maturation and subsequent loss of the antigen-processing function can occur before sufficient MHC class II processing of M. tuberculosis antigens has occured, although CD1-based antigen processing persists 128 . It was also observed that lung DCs from mice that were infected with M. tuberculosis by In vivo studies present a more complex situation in which to assess the effects of mycobacterial infection of APCs on MHC class II molecule expression. Several studies 115, 135, 136 have suggested that some macro phage subsets have decreased expression of MHC class II molecules at certain stages during mycobacterial infection of the lung. As noted above, simply measuring MHC class II molecule levels might underestimate the inhibition of antigen presentation, as some effects on antigen processing can only be assessed functionally. In addition, in vivo studies have not distinguished the small proportion of APCs that are directly infected by mycobacteria from the large proportion of uninfected APCs that are present in infected tissue (for example, only ~1% of macro phages are infected at the peak of pulmonary infection after aerosol infection of mice with M. bovis BCG 117 ). T cell responses generate IFNγ, which induces MHC class II molecule expression in macrophages. Thus, the inflammatory response to mycobacterial infection increases expression of MHC class II molecules in most of the uninfected macrophages (as observed in mycobacteria-induced exudates 137 ), but this does not reveal the level of MHC class II molecule expression in the small proportion of these cells that are actually infected with mycobacteria. To determine whether M. tuberculosis inhibits the expression of MHC class II molecules in APCs in vivo, it is necessary to distinguish the small proportion of infected APCs from uninfected APCs, by infection with GFP-expressing mycobacteria, for example. when this approach was taken for the aerosol infection of mice with M. bovis BCG, lung macrophages and DCs that harboured mycobacteria were found to have lower levels of MHC class II molecule expression than cells from the same lungs that did not harbour mycobacteria 117 . However, when a similar approach was used to study lung cells from mice infected with M. tuberculosis H37Rv, no significant changes were observed in the expression levels of MHC class II molecules in macrophages 21 . Thus, in vivo studies have produced varying results with different models, but several reports using different approaches suggest that small subsets of lung APCs that harbour mycobacteria have suppressed levels of MHC class II molecule expression, even though expression is increased in other APCs. Importantly, inhibition of MHC class II molecule expression in even a small proportion of APCs would provide sufficient niches for the small number of M. tuberculosis bacilli that persist during chronic infection.
Explaining the differing MHC class II regulation
Are there teleological models to explain why APCs decrease synthesis of MHC class II molecules after TLR signalling, and why macrophages and DCs differ in their post-translational control of MHC class II molecule expression after TLR signalling? For DCs, TLR stimulation results in a final burst of MHC class II molecule synthesis at the time of PAMP exposure, which should correspond to the time of exposure to, and processing of, other pathogen-derived antigens. Subsequently, MHC class II molecule synthesis declines, and expression is prolonged for the cohort of peptide-MHC class II complexes that is enriched in pathogen-derived peptides. This focuses antigen presentation by DCs on the presentation of pathogenderived antigens, and the prolongation of this presentation allows for efficient priming of naive T cells in lymph nodes. This might explain why CD4 + T cell responses are readily induced in animals and humans after M. tuberculosis infection.
Macrophages differ from DCs in their roles in both antigen presentation and its regulation. Although macrophages are not major contributors to the priming of T cell responses, they have an important role in presenting antigen to effector T cells at sites of infection. This is crucial for T cell effector functions that are important for host defence (such as cytokine release), but these effector functions can also seriously damage host tissues if they are induced to excessive levels. Macrophages, like DCs, decrease MHC class II molecule synthesis after prolonged TLR signalling, but the stability of MHC class II molecules on macrophages is not enhanced by this signalling. Therefore, expression of MHC class II molecules decays after prolonged TLR signalling.
we propose that this decay of APC function could be a homeostatic downregulatory mechanism to limit effector T cell activation and prevent excessive tissue damage. As a consequence of this mechanism, MHC class II antigen presentation might be downregulated in macrophages that are directly infected with intra-vacuolar pathogens that provide chronic TLR stimulation. Other uninfected macrophages could remain uninhibited and competent for antigen presentation, so the downregulatory mechanism limits, but does not eliminate, antigen presentation in infected tissue. In the context of chronic bacterial infections, such as M. tuberculosis infection, delayed downregulation might allow sufficient T cell activation to induce adequate host defences. The ability of M. tuberculosis to survive in phagosomal compartments and inactivate microbicidal molecules allows its persistence in macrophages until MHC class II antigen presentation is inhibited, reducing the ability of CD4 + T cells to recognize infected cells and, thus, providing a niche for survival and evasion of CD4 + T cell-mediated immunity.
The infected APC as a niche for immune evasion One of the paradoxes of the host-pathogen interaction in M. tuberculosis infection is that the organism is rich in cell wall and secreted molecules that are TLR agonists and in antigens that readily prime CD4 + T cell responses, but it can survive and persist in APCs, avoiding elimination. CD4 + T cells are essential for the control of primary infection and necessary for ongoing immune surveillance to control the persistent infection that forms the reservoir for reactivation TB, which is the most common form of the disease worldwide. There are many mechanisms involved in the survival of M. tuberculosis, including its ability to prevent phagosome fusion with lysosomes and resist the microbicidal molecules (such as superoxide, nitric oxide and defensins) that are produced by phagocytes. The host's tendency to form granulomas might interfere with cell trafficking and with the access of T cells to M. tuberculosis-infected macrophages.
The ability of M. tuberculosis to inhibit MHC class II antigen presentation through prolonged stimulation of TLR2, thereby directly inhibiting its recognition by CD4 + T cells, is an additional means of immune evasion. This mechanism takes advantage of a natural regulatory mechanism of macrophages to decrease MHC class II molecule expression and antigen presentation in order to down-modulate the excessive inflammation that would be induced by prolonged stimulation of the innate immune system. However, the pathogen must survive its initial interaction with macrophages and deliver ligand to TLR2 on the cell surface or phagosomal membrane. This mechanism could be especially relevant during the chronic phase of infection, when few organisms are present and immune surveillance is focused on macrophages. In this way, M. tuberculosis is able to turn a liability (namely, a cell wall that is rich in TLR agonists) into a survival mechanism that relies on inhibition of macrophage-mediated presentation of M. tuberculosis antigens and induction of effector T cell responses.
